RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+12.07%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.23B
AUM Growth
+$1.23B
(+18%)
Cap. Flow
+$106M
Cap. Flow
% of AUM
8.59%
Top 10 Holdings %
Top 10 Hldgs %
30.7%
Holding
101
New
8
Increased
39
Reduced
39
Closed
6
Top Buys
| 1 |
Inspire Medical Systems
INSP
|
$22.2M |
| 2 |
Exact Sciences
EXAS
|
$21.8M |
| 3 |
Medtronic
MDT
|
$14.4M |
| 4 |
Novo Nordisk
NVO
|
$11.9M |
| 5 |
CVS Health
CVS
|
$11.6M |
Top Sells
| 1 |
UnitedHealth
UNH
|
$19.1M |
| 2 |
Elevance Health
ELV
|
$18.4M |
| 3 |
Oscar Health
OSCR
|
$11.4M |
| 4 |
Cigna
CI
|
$11.3M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$9.67M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Abbott
ABT
$230B
| $15.4M | 1.25% |
135,000
-10,000
| -7% | -$1.14M |
|
|
ITCI
27
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $15M | 1.22% |
205,500
+63,500
| +45% | +$4.65M |
|
28
McKesson
MCK
$85.9B
| $14.9M | 1.21% |
30,117
+117
| +0.4% | +$57.8K |
|
29
Glaukos
GKOS
$5.42B
| $14.5M | 1.17% |
111,000
+61,000
| +122% | +$7.95M |
|
|
30
Cigna
CI
$80.2B
| $14.4M | 1.17% |
41,685
-32,486
| -44% | -$11.3M |
|
31
Align Technology
ALGN
$9.59B
| $14M | 1.14% |
55,000
-1,500
| -3% | -$381K |
|
|
32
Alnylam Pharmaceuticals
ALNY
$58.6B
| $13.8M | 1.12% |
50,350
-35,150
| -41% | -$9.67M |
|
33
Dynavax Technologies
DVAX
$1.19B
| $13.3M | 1.08% |
1,190,000
-42,361
| -3% | -$472K |
|
34
Biogen
BIIB
$20.5B
| $13M | 1.06% |
67,100
-17,700
| -21% | -$3.43M |
|
|
35
Novo Nordisk
NVO
$252B
| $11.9M | 0.97% |
+100,000
| New | +$11.9M |
|
|
36
CVS Health
CVS
$93B
| $11.6M | 0.94% |
+184,000
| New | +$11.6M |
|
37
IQVIA
IQV
$31.4B
| $11.4M | 0.92% |
48,000
+17,000
| +55% | +$4.03M |
|
38
Axsome Therapeutics
AXSM
$6.09B
| $11M | 0.89% |
122,600
-5,000
| -4% | -$449K |
|
39
Apellis Pharmaceuticals
APLS
$3.51B
| $10.6M | 0.86% |
367,500
+312,105
| +563% | +$9M |
|
40
Jazz Pharmaceuticals
JAZZ
$7.99B
| $10.4M | 0.84% |
93,000
-21,000
| -18% | -$2.34M |
|
41
Molina Healthcare
MOH
$9.6B
| $10.2M | 0.83% |
29,600
+22,600
| +323% | +$7.79M |
|
42
Cencora
COR
$57.2B
| $10.2M | 0.82% |
45,150
-6,350
| -12% | -$1.43M |
|
43
Iovance Biotherapeutics
IOVA
$800M
| $9.88M | 0.8% |
1,052,500
+132,500
| +14% | +$1.24M |
|
44
Humana
HUM
$37.5B
| $9.82M | 0.8% |
+31,000
| New | +$9.82M |
|
45
Cytokinetics
CYTK
$5.98B
| $9.53M | 0.77% |
180,500
-17,015
| -9% | -$898K |
|
46
Insmed
INSM
$30.3B
| $9.45M | 0.77% |
129,513
+30,000
| +30% | +$2.19M |
|
47
Insulet
PODD
$24.2B
| $9.31M | 0.76% |
40,000
-6,500
| -14% | -$1.51M |
|
48
Nuvalent
NUVL
$5.74B
| $9.21M | 0.75% |
90,000
+7,250
| +9% | +$742K |
|
49
Centene
CNC
$14.8B
| $8.81M | 0.71% |
116,982
-81,500
| -41% | -$6.14M |
|
50
Stryker
SYK
$149B
| $8.31M | 0.67% |
23,000
+5,000
| +28% | +$1.81M |
|